Facing ultra-high-risk multiple myeloma often feels like running out of road. Patients who cannot undergo transplant and face relapse desperately need new hope. This report looks at a specific drug combination used after CAR-T cell therapy. It targets those with limited treatment options.
Two patients received a maintenance regimen called ILD. This mix included lisaftoclax, ixazomib, and dexamethasone. The result was promising. Both individuals achieved durable disease control with MRD negativity. MRD negativity means doctors could not find any cancer cells in their blood. This suggests the treatment worked well for these specific people.
However, we must look closely at the evidence. This report used a case report design involving only two people. The study does not prove causality through a controlled trial. Certainty remains low because the sample size is so small. The report did not share safety details, so we do not know about side effects.
Despite these limits, this offers a potential path for patients with very few choices. Formal evaluations of this regimen may be meaningful. It highlights a possible direction for future research without guaranteeing success for everyone. We need more data to confirm if this helps others.
